ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
The delayed authorization and slow development of coronavirus vaccines in Japan have exposed deeper problems. (Source photo by Takaki Kashiwabara)
Datawatch

Japan falling behind in developing biopharmaceutical drugs

Trade deficit in medicines likely to top $26bn in 2021 due to weak R&D

TAKURO KUSASHIO and KOHEI YAMADA, Nikkei staff writers | Japan

TOKYO -- Japan's trade deficit in medical goods is likely to top 3 trillion yen ($26.45 billion) in 2021 for the first time as the nation loses its market presence in the era of biopharmaceutical drugs.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more